fluoxetine has been researched along with Hepatitis C, Chronic in 6 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Hepatitis C, Chronic: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After approval by the institutional ethics committee, 20 adult patients with chronic hepatitis C, but with no history of other liver diseases, were prospectively admitted to the study, which included phenotyping by means of a dextromethorphan test and evaluation of fluoxetine and norfluoxetine pharmacokinetic parameters (the area under the serum concentration-time curve, maximum serum concentration, time to reach the maximum serum concentration and terminal elimination half-life) before and after 2 months of continuous peginterferon-α-2b therapy." | 7.76 | Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α. ( Donnini, D; Franceschi, L; Furlanut, M; Sechi, L; Soardo, G, 2010) |
| "More than 20% of chronic hepatitis C (CHC) patients receiving interferon-alpha (IFN-α)-based anti-hepatitis C virus (HCV) therapy experienced significant depression, which was relieved by treatment with fluoxetine." | 3.80 | Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways. ( Bai, CH; Chong, LW; Lai, HW; Liao, CS; Lin, YM; Pu, CY; Su, HC; Tsai, PJ; Tsai, YS; Tsao, CW; Young, KC, 2014) |
| "After approval by the institutional ethics committee, 20 adult patients with chronic hepatitis C, but with no history of other liver diseases, were prospectively admitted to the study, which included phenotyping by means of a dextromethorphan test and evaluation of fluoxetine and norfluoxetine pharmacokinetic parameters (the area under the serum concentration-time curve, maximum serum concentration, time to reach the maximum serum concentration and terminal elimination half-life) before and after 2 months of continuous peginterferon-α-2b therapy." | 3.76 | Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α. ( Donnini, D; Franceschi, L; Furlanut, M; Sechi, L; Soardo, G, 2010) |
| " In addition, the study was extended to evaluate the pharmacokinetic interaction between DCV and a co-prescribed antidepressant drug, fluoxetine (FLX) in real blood samples, collected from volunteering patients who were diagnosed with HCV and treated with DCV alone or combined with FLX." | 1.51 | A clinical study for the evaluation of pharmacokinetic interaction between daclatasvir and fluoxetine. ( Abdul-Rahman, E; Ali, R; Elsutohy, MM; Khorshed, A; Oraby, M, 2019) |
| " Because of its sensitivity, this HPLC/MS/MS method is suitable both for routine therapeutic drug monitoring and for pharmacokinetic studies, due to its low limits of quantification." | 1.35 | A simple method to monitor serum concentrations of fluoxetine and its major metabolite for pharmacokinetic studies. ( Faggiani, A; Franceschi, L; Furlanut, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Schloer, S | 1 |
| Brunotte, L | 1 |
| Mecate-Zambrano, A | 1 |
| Zheng, S | 1 |
| Tang, J | 1 |
| Ludwig, S | 1 |
| Rescher, U | 1 |
| Oraby, M | 1 |
| Khorshed, A | 1 |
| Abdul-Rahman, E | 1 |
| Ali, R | 1 |
| Elsutohy, MM | 1 |
| Young, KC | 1 |
| Bai, CH | 1 |
| Su, HC | 1 |
| Tsai, PJ | 1 |
| Pu, CY | 1 |
| Liao, CS | 1 |
| Lin, YM | 1 |
| Lai, HW | 1 |
| Chong, LW | 1 |
| Tsai, YS | 1 |
| Tsao, CW | 1 |
| Franceschi, L | 2 |
| Faggiani, A | 1 |
| Furlanut, M | 2 |
| Soardo, G | 1 |
| Donnini, D | 1 |
| Sechi, L | 1 |
| Mistler, LA | 1 |
| Brunette, MF | 1 |
| Rosenberg, SD | 1 |
| Vidaver, RM | 1 |
| Luckoor, R | 1 |
| Iber, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-11-30 | Withdrawn (stopped due to Study timeline is not feasible) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for fluoxetine and Hepatitis C, Chronic
| Article | Year |
|---|---|
Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Fluoxetine; Hepatitis C | 2021 |
A clinical study for the evaluation of pharmacokinetic interaction between daclatasvir and fluoxetine.
Topics: Area Under Curve; Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Drug Stabilit | 2019 |
Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways.
Topics: Alanine Transaminase; Antiviral Agents; Cell Line; Cell Survival; Cohort Studies; Drug Therapy, Comb | 2014 |
A simple method to monitor serum concentrations of fluoxetine and its major metabolite for pharmacokinetic studies.
Topics: Antidepressive Agents, Second-Generation; Area Under Curve; Calibration; Chromatography, High Pressu | 2009 |
Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α.
Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Area Under Curve; Drug Interactio | 2010 |
Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha.
Topics: Adult; Alcoholics Anonymous; Alcoholism; Anticonvulsants; Antidepressive Agents, Second-Generation; | 2006 |